Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study.

Author: Meng CHAI ¹ ; Haitao ZHANG ² ; Lixia YANG ¹ ; Jing LIANG ¹ ; Hongya HAN ¹ ; Xiaoli LIU ¹ ; Xiaoteng MA ¹ ; Yan LIU ¹ ; Dongmei SHI ¹ ; Yingxin ZHAO ¹ ; Yuyang LIU ¹ ; Yujie ZHOU ¹
Author Information

1. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing 100029, China.
2. Department of Cardiology, Air Force Medical Center, Beijing 100142, China.
Publication Type:Journal Article
MeSH: Humans; Cardiovascular Diseases/chemically induced*; East Asian People; Risk Factors; Heart Disease Risk Factors; Lipids; Anticholesteremic Agents/adverse effects*; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome
From: Chinese Medical Journal 2023;136(11):1358-1360
CountryChina
Language:English